## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($43.17)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Loomis Sayles & Co. L P Trims Position in Veracyte, Inc. $VCYT**
- Source: MarketBeat | 20251204T045138 | Somewhat-Bullish | Relevance: 100%
- Loomis Sayles & Co. L P reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 15.2% in the second quarter, selling 73,250 shares and ending with 409,471 shares valued at approximately $11.07 million. Despite this trimming, other major institutional investors like Vanguard Group Inc. and Artisan Partners Limited Partnership significantly increased their holdings. Veracyte surpassed Q2 earnings estimates with an EPS of $0.51 and revenue of $131.9 million, leading to "Moderate Buy" consensus and price target upgrades from analysts.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $48 | $40 | +20% |
| 2025-11-11 | Morgan Stanley | $40 | $28 | +43% |
| 2025-11-05 | UBS | $48 | $42 | +14% |
| 2025-11-05 | Canaccord Genui | $43 | $40 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |
| 2025-11-11 | Morgan Stanley | main | Underweight |
| 2025-11-05 | UBS | main | Buy |
| 2025-11-05 | Canaccord Genui | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 25 ($5.77M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.83) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $5.8M in recent transactions.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Analyst target momentum: 6 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Analyst sentiment positive (6 raises, avg +17%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.4B |
| Beta | 1.83 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 7.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 29.6 |
| Current P/E | 28.8 |
| YoY Growth | -2.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 6.4% to 0.3% (-6.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.7pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.29% (CS: 57) | Neutral |
| RSI_14 | 65.0 | Neutral |
| MACD Histogram | 0.24 | Bullish |
| vs SMA20 | 1.088x | Above |
| vs SMA50 | 1.222x | Above |
| vs SMA200 | 1.491x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $47.41
- **Stop Loss:** $43.17 (8.9% risk)
- **Target:** $51.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 117
- **Position Value:** $5,546.97
- **Portfolio %:** 5.55%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*